-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

331.P1.24 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster I

Symposia: Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Autoimmune disorders, Fundamental Science, Adult, Epidemiology, Autoimmune hemolytic anemia, Platelet disorders, Clinical Research, Health outcomes research, GVHD, Diseases, Immune Disorders, Thrombocytopenias, Patient-reported outcomes, Treatment Considerations, Biological therapies, Thrombotic disorders, Real-world evidence, Adverse Events, Infusion, Monoclonal Antibody Therapy, Study Population, Human
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)

José Diogo Oliveira, PhD1*, Bruna Cardoso Jacintho2*, Bruna Mazetto3*, Erich Vinicius De Paula, MD, PhD4 and Fernanda A. Orsi, MD, PhD5*

1University of Campinas (UNICAMP), Campinas, LA, Brazil
2School of Medical Sciences, University of Campinas (UNICAMP), Campinas, AC, Brazil
3Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
4University of Campinas, Campinas, SP, Brazil
5Department of Pathology, School of Medical Sciences, Unicamp, Campinas, Brazil

Raj S. Kasthuri, MBBS1, Ryan Kemper2*, Brittany Holshouser3*, Elizabeth Powell3*, Allison B Carroll3*, Sheh-Li Chen, PharmD4, Daniel Crona, PhD, PharmD5* and Lee Ann Jones, PharmD3*

1Division of Hematology, Univ. of North Carolina at Chapel Hill, Chapel Hill, NC
2Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC
3Department of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC
4Department of Pharmaccy, University of North Carolina Medical Center, Chapel Hill, NC
5Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC

Anne K Hubben, MD1, Jenna Brown, B.A.2*, Linda Burke3*, Len Woodward4*, Clare Martin, MSc, MS5*, Keith R. McCrae, MD1,6 and Shruti Chaturvedi, MBBS2

1Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
3aHUS Alliance Global Action, Cape Elizabeth, ME
4aHUS Alliance Global Action, Knutsford, Cheshire, United Kingdom
5USTMA, Columbus, OH
6Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, OH

Udit Nangia, MD1, Leland Metheny, MD2 and Neeraj Mahajan, MD3*

1University Hospitals - Parma Medical Center, Vernon Hills, IL
2Department of Hematology and Stem Cell Transplant, University Hospitals Seidman Cancer Center, Cleveland, OH
3University Hospitals - Parma Medical Center, Parma, OH

Sakditad Saowapa, MD1, Natchaya Polpichai, MD2*, Natapat Chaisidhivej, MD3*, Manasawee Tanariyakul4*, Chalothorn Wannaphut, MD4, Pojsakorn Danpanichkul, MD1*, Hector J Garcia Pleitez, MD1, Diego Olavarria Bernal, MD1*, Phuuwadith Wattanachayakul, MD5*, Ben Ponvilawan, MD6*, Pharit Siladech, MD7* and Lukman Tijani, MD8*

1Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX
2Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL
3Division of Gastroenterology and Hepatology, University of Nebraska Medical Center, Omaha, NE, USA, Omaha, NE
4Department of Internal Medicine, University of Hawaii John A.Burns School of Medicine, Honolulu, HI
5Albert Einstein Healthcare Network, Philadelphia, PA
6Department of Internal Medicine, University of Missouri at Kansas City, Kansas City, MO
7Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
8Department of Hematology and Oncology, Texas Tech University Health Sciences Center, Lubbock, TX

Udit Nangia, MD1, Leland Metheny, MD2 and Neeraj Mahajan, MD3*

1University Hospitals - Parma Medical Center, Vernon Hills, IL
2Department of Hematology and Stem Cell Transplant, University Hospitals Seidman Cancer Center, Cleveland, OH
3University Hospitals - Parma Medical Center, Parma, OH

Rachel R Leger, B.S.1*, Rajiv K Pruthi, M.B.B.S.1,2, Adam Kanack, PhD1, Jansen N Seheult, M.D.3*, Noah Splinter, MS1* and Anand Padmanabhan, MBBS, PhD4

1Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
2Comprehensive Hemophilia Center and Special Coagulation Laboratory, Division of Hematopathology, Mayo Clinic, Rochester, MN
3Division of Hematopathology, Mayo Clinic, Rochester, MN
4Department of Laboratory Medicine, Mayo Clinic, Rochester, MN

Reid C. Gallant, MD, MSc1, Melanie St John2*, Yang Liu, MMath2*, Madison Cranstone2*, John G. Kelton, MD, FRCPC2, Ishac Nazy, PhD3 and Donald Arnold, MD2

1Department of Medicine, McMaster University, Mississauga, ON, Canada
2Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada
3Department of Medicine, McMaster University, Hamilton, ON, Canada

Aroob Sweidan, MD1, Rachel L Brancamp, MD2*, Ileana Lopez-Plaza, MD2, Gordon Jacobsen3* and Philip Kuriakose, MD1

1Hematology and Oncology, Henry Ford Health, Detroit, MI
2Pathology and Transfusion Medicine, Henry Ford Health, Detroit, MI
3Public Health Sciences, Henry Ford Health, Detroit, MI

*signifies non-member of ASH